HRA Pharma to launch ellaOne (ulipristal acetate) training roadshow
23 April 2015 | By Victoria White
Now that ellaOne is available in UK Pharmacy without prescription, HRA Pharma UK is launching a training programme to support its introduction...
List view / Grid view
News
Bionomics initiates Phase II clinical study of BNC210 for the treatment of anxiety and depression
22 April 2015 | By Victoria White
Bionomics has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression...
24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv for maintenance treatment of opioid dependence
22 April 2015 | By Victoria White
Orexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence...
Updated results from Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma announced
22 April 2015 | By Victoria White
Cortice Biosciences has announced interim results a Phase 1/2 trial evaluating TPI 287 plus bevacizumab for the treatment of glioblastoma multiforme...
Merck reaffirms commitment to developing therapeutics to fight infectious diseases
22 April 2015 | By Victoria White
Merck has reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases...
Quotient Clinical completes innovative first-in-human program
22 April 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit...
Nimbus initiates Phase I clinical programme for NDI-010976 for the treatment of NASH
22 April 2015 | By Victoria White
Nimbus Therapeutics has initiated a Phase I clinical programme for NDI-010976 for the treatment of NASH and related fatty liver disease-spectrum disorders...
Xalkori receives Breakthrough Therapy designation for the treatment of patients with ROS1-positive non-small cell lung cancer
22 April 2015 | By Victoria White
Pfizer’s XALKORI has received Breakthrough Therapy designation from the FDA for the potential treatment of patients with ROS1-positive NSCLC...
Teva makes $40 billion offer for Mylan
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
GW initiates second Phase 3 trial of Epidiolex in Dravet syndrome
22 April 2015 | By Victoria White
GW Pharmaceuticals has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare form of childhood epilepsy...
Phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia
21 April 2015 | By Victoria White
Pfizer Phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)...
Merck KGaA and Pfizer initiate Phase III study with avelumab in patients with stage IIIb/IV non-small cell lung cancer
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
Cobalt receives the 2015 Queen’s Award for Enterprise
21 April 2015 | By Cobalt Light Systems
Cobalt Light Systems has been named as a recipient of the prestigious 2015 Queen’s Award for Enterprise...
Syrris Atlas Calorimeter benefits process scale-up
21 April 2015 | By kdm communications
A Syrris Atlas Calorimeter is proving advantageous to the Kyushu works manufacturing technology department of Nippon Steel & Sumikin Chemical Co., Ltd. in Japan, aiding scale-up of new product processes...
TetraLogic and Merck collaborate on the evaluation of birinapant in combination with KEYTRUDA in solid tumours
21 April 2015 | By Victoria White
TetraLogic and Merck are to collaborate to evaluate a combination of birinapant and KEYTRUDA in patients with relapsed or refractory solid tumours...
